- Home
- LIME vs AUPH Comparison
LIME vs AUPH Comparison
Compare LIME & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIME | AUPH |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LIME | AUPH |
|---|---|---|
| Price | $17.90 | $16.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $35.71 | $18.29 |
| AVG Volume (30 Days) | 418.8K | ★ 862.5K |
| Earning Date | 11-03-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 5.47 | 0.76 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $21.48 | $16.65 |
| Revenue Next Year | $16.87 | $17.73 |
| P/E Ratio | ★ $3.37 | $22.51 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.20 | $13.52 |
| 52 Week High | $44.38 | $19.25 |
Technical Indicators
Market Signals| Indicator | LIME | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 29.68 | 47.46 |
| Support Level | N/A | $15.61 |
| Resistance Level | $27.16 | $16.48 |
| Average True Range (ATR) | 2.22 | 0.55 |
| MACD | -0.58 | -0.08 |
| Stochastic Oscillator | 5.68 | 28.13 |
Price Performance
Historical ComparisonAbout LIME Neutron Holdings Inc. Common Stock
Neutron Holdings Inc is a micromobility company that provides rentals of shared electric scooters (e-scooters) and electric bicycles (e-bikes) through its platform (the Rider App) to be used for short distances in various cities and municipalities around the world.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.